Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lipid Sciences has received the third selective delipidation patent, which further extends the depth of patent coverage surrounding the company's HDL therapy platform, and in particular, the proprietary selective delipidation process.
Subscribe to our email newsletter
These particular patents are said to be a critical component of the company’s strategic plan to maximize the value of this strong IP position and the recent clinical trial data to pursue a corporate partnership related to Lipid Sciences’s HDL selective delipidation.
Lewis Meyer, president and CEO of Lipid Sciences, said: “Our selective delipidation process ‘energizes’ a patient’s own HDL particles to pick up excess lipids from plaque in the arterial walls and transport those lipids to the liver to be processed and naturally excreted from the body. Our proprietary process has the potential to address a significant unmet clinical need in cardiovascular disease.”